DSM announces expiration of waiting period under Hart-Scott-Rodino Act


HEERLEN, NETHERLANDS--(Marketwire -06/06/12)- Royal DSM (DSM),the global Life Sciences and MaterialsSciences company, announced today the expiration of the mandatory waitingperiodunder the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,forits previously announced tender offer for all outstanding shares of commonstockof Kensey Nash Corporation (KNSY) at a price of $38.50 per share(the"Offer"). This condition of the Offer is thus satisfied.

The Offer remains subject to the satisfaction of certain other conditions.TheOffer is scheduled to expire at 12:00 midnight (New York City time) at theendof Monday, June 18, 2012, unless the Offer is extended.

Kensey Nash

Kensey Nash is a medical device company primarily focused onregenerativemedicine utilizing its proprietary collagen and synthetic polymertechnology.The company is recognized as a leader for innovative productdevelopment andunique technology in the field of resorbable biomaterials. The companyhas anextensive range of products, which are sold through strategicpartners inmultiple medical markets, including the cardiology, orthopedic, sportsmedicine,spine, trauma, craniomaxillofacial and general surgery markets. Formoreinformation, visit http://www.kenseynash.com.

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition andmaterials. By connecting its unique competences in Life Sciences andMaterialsSciences DSM is driving economic prosperity, environmental progress andsocialadvances to create sustainable value for all stakeholders. DSM deliversinnovative solutions that nourish, protect and improve performance inglobalmarkets such as food and dietary supplements, personal care, feed,pharmaceuticals, medical devices, automotive, paints, electrical andelectronics, life protection, alternative energy and bio-based materials.DSM's22,000 employees deliver annual net sales of around EUR9 billion. Thecompany islisted on NYSE Euronext. More information can be found at www.dsm.com.

Press release-pdf:http://hugin.info/130663/R/1617576/516198.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE


For more information:
DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017
fax +31 (0) 45 5740680
e-mail Email Contact
DSM Investor Relations
Hans Vossen
tel. +31 (0) 45 5782864
fax +31 (0) 10 4590275
e-mail Email Contact
Kensey Nash
Joseph W. Kaufmann
Tel. +1 484 713 2100

View Comments (0)